Expression and prognostic value of epithelial‑to‑mesenchymal transition and cancer stem cellmarkersin primary lesions and liver metastases of colorectal cancers

Li,Cong; Liu,Ji-Yan; Jiang,Dan; Qiu,Meng

doi:10.3892/ol.2021.12760

Expression and prognostic value of epithelial‑to‑mesenchymal transition and cancer stem cellmarkersin primary lesions and liver metastases of colorectal cancers

Authors:
- Cong Li
- Ji-Yan Liu
- Dan Jiang
- Meng Qiu
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 27, 2021 https://doi.org/10.3892/ol.2021.12760
Article Number: 499
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells (CSCs) and epithelial mesenchymal transition (EMT) markers are considered useful indicators associated with metastasis and prognosis of colorectal cancers (CRCs). However, only a few studies have focused on the expression of these useful markers in metastases. Metastasectomy is widely used in advanced CRCs, and thus the postoperative prognostic factors are worth investigating. The present study investigated the consistency and differences of target proteins between primary and metastatic lesions of colorectal cancer, and discussed the prognostic indicators following resection of colorectal liver metastases. Clinical data of 56 patients with liver metastases from colorectal cancer were collected and the expression levels of target proteins (Ki‑67, CD133, CD44, Snail, E‑cadherin and β‑catenin) were detected in primary tumor and matched liver metastases via immunohistochemistry analysis. Paired comparison between both tissue types was performed. The prognostic values of the target proteins for resectable colorectal cancer liver metastases were assessed. No significant differences were observed between the primary tissues and metastatic tissues. The consistency rates of these protein expression levels ranged from 51.8‑78.6%. The maximum diameter of the liver metastases was <5 cm. Low Snail expression in metastases was associated with a longer overall survival (OS) time following resection of colorectal liver metastases. Furthermore, N0 stage and low carcinoembryonic antigen levels were associated with a longer progression‑free survival time. Notably, no significant differences were observed in expression levels of the target proteins between the primary tumors and liver metastases. Taken together, the results of the present study suggest that Snail expression in liver metastases may be used as a novel independent prognostic factor for OS following resection of colorectal liver metastases.

View Figures

View References

1	Stewart BW and Wild CP: World Cancer Report 2014. World Health Organization; 2014
2	Chen WQ, Zheng RS and Zhang SW: Report of Cancer Incidence and Mortality in China, 2012. China Cancer. 25:1–8. 2016.PubMed/NCBI
3	Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN and Parks RW: Guidelines for resection of colorectal cancer liver metastases. Gut. 55 (Suppl 3):iii1–iii8. 2006. View Article : Google Scholar : PubMed/NCBI
4	De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K and Peeters M: Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol. 22:7215–7225. 2016. View Article : Google Scholar : PubMed/NCBI
5	Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ and Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 235:759–766. 2002. View Article : Google Scholar : PubMed/NCBI
6	Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, et al: High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol. 29:1083–1090. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yan X, Wang K, Wang Q, et al: Prognostic evaluation of clinical scoring systems for patients undergoing resection of colorectal cancer liver metastases. Chin J Hepatobiliary Surg. 21:388–392. 2015.PubMed/NCBI
8	Spelt L, Andersson B, Nilsson J and Andersson R: Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Eur J Surg Oncol. 38:16–24. 2012. View Article : Google Scholar : PubMed/NCBI
9	Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D; Association Française de Chirurgie, : Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 77:1254–1262. 1996. View Article : Google Scholar : PubMed/NCBI
10	Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
11	Yeung KT and Yang J: Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
12	Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, et al: The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 8:327ra262016. View Article : Google Scholar : PubMed/NCBI
13	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
14	Gao D and Li S: Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. Cancer Microenviron. 6:213–230. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, et al: Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncol. 28:604–610. 2017. View Article : Google Scholar : PubMed/NCBI
16	Oakley GJ III, Denning KL, Graffeo V, Griswold DC, Davis AR and Brown LG: Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases. Pathol Res Pract. 212:995–1003. 2016. View Article : Google Scholar : PubMed/NCBI
17	Aprile G, Casagrande M, De Maglio G, Fontanella C, Rihawi K, Bonotto M, Pisa FE, Tuniz F, Pizzolitto S and Fasola G: Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol. 13:135–144. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
19	Shibue T and Weinberg RA: EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ren F, Sheng WQ and Du X: CD133: A cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 19:2603–2611. 2013. View Article : Google Scholar : PubMed/NCBI
21	Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG and Wu K: The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 8:3783–3792. 2015.PubMed/NCBI
22	Zhang P, Hu P, Shen H, Yu J, Liu Q and Du J: Prognostic role of Twist or Snail in various carcinomas: A systematic review and meta-analysis. Eur J Clin Invest. 44:1072–1094. 2014. View Article : Google Scholar : PubMed/NCBI
23	He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis. PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
24	Li LF, Wei ZJ, Sun H and Jiang B: Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis. World J Gastroenterol. 20:12313–12321. 2014. View Article : Google Scholar : PubMed/NCBI
25	Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, et al: CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis. Ann Surg Oncol. 23:1916–1923. 2016. View Article : Google Scholar : PubMed/NCBI
26	Pitule P, Cedikova M, Daum O, Vojtisek J, Vycital O, Hosek P, Treska V, Hes O, Kralickova M and Liska V: Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients. BioMed Res Int. 2014:4321392014. View Article : Google Scholar : PubMed/NCBI
27	Jang TJ: Differential membranous E-cadherin expression, cell proliferation and O-GlcNAcylation between primary and metastatic nodal lesion in colorectal cancer. Pathol Res Pract. 212:113–119. 2016. View Article : Google Scholar : PubMed/NCBI
28	Buhmeida A, Elzagheid A, Algars A, Collan Y, Syrjänen K and Pyrhönen S: Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica. 116:1–9. 2008.PubMed/NCBI
29	Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F and Xue Y: Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 8:e812642013. View Article : Google Scholar : PubMed/NCBI
30	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
31	Francí C, Gallén M, Alameda F, Baró T, Iglesias M, Virtanen I and García de Herreros A: Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. PLoS One. 4:e55952009. View Article : Google Scholar
32	Gabbert HE, Mueller W, Schneiders A, Meier S, Moll R, Birchmeier W and Hommel G: Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer. 69:184–189. 1996. View Article : Google Scholar : PubMed/NCBI
33	Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y and Hirohashi S: Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology. 59:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
34	Kim W, Kim M and Jho EH: Wnt/β-catenin signalling: From plasma membrane to nucleus. Biochem J. 450:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
35	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kong D, Li Y, Wang Z and Sarkar FH: Cancer stem cells and Epithelial-to-Mesenchymal Transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel). 3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
37	Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al: Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527:472–476. 2015. View Article : Google Scholar : PubMed/NCBI
38	Danner BC, Gerdes JS, Jung K, Sander B, Enders C, Liersch T, Seipelt R, Gutenberg A, Gunawan B, Schöndube FA, et al: Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases. Cancer Genet. 204:122–128. 2011. View Article : Google Scholar : PubMed/NCBI
39	Sobottka B, Pestalozzi B, Fink D, Moch H and Varga Z: Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. OncoImmunology. 5:e11532082016. View Article : Google Scholar : PubMed/NCBI
40	Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 104:1020–1026. 2011. View Article : Google Scholar : PubMed/NCBI
41	Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M and Perou CM: Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 132:523–535. 2012. View Article : Google Scholar : PubMed/NCBI
42	Wang BB, Li ZJ, Zhang FF, Hou HT, Yu JK and Li F: Clinical significance of stem cell marker CD133 expression in colorectal cancer. Histol Histopathol. 31:299–306. 2016.PubMed/NCBI
43	Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B and Russo A: Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 99:150–157. 2016. View Article : Google Scholar : PubMed/NCBI